Ignite Creation Date:
2024-05-05 @ 11:19 AM
Last Modification Date:
2024-10-26 @ 9:05 AM
Study NCT ID:
NCT00006493
Status:
COMPLETED
Last Update Posted:
2005-06-24
First Post:
2000-11-14
Brief Title:
Rosiglitazone in the Treatment of HIV-Associated Hyperlipidemia
Sponsor:
National Center for Research Resources NCRR
Organization:
National Center for Research Resources NCRR
Study Overview
Official Title:
None
Status:
COMPLETED
Status Verified Date:
2004-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this research is to study the effects of rosiglitazone a drug usually taken for Type II diabetes on HIV-associated hyperlipidemia HIV-associated lipodystrophy is a medical condition characterized by gradual changes in the distribution of body fat The body fat located in the extremities and face disappears while body fat around the abdomen and upper back increases Certain biochemical changes occur in association with these changes in fat distribution Lipid levels particularly serum triglycerides are increased HDL the good cholesterol is decreased Higher than normal level of insulin or insulin resistance is also found in this condition This latter condition is one of the hallmarks of Type II diabetes The protease inhibitors a class of HIV medications are associated with the occurrence of HIV-associated lipodystrophy It has been suggested that a biochemical pathway known as the peripheral peroxisomal activating receptor PPAR gamma system is blocked leading to the onset of this condition
Rosiglitazone is a new drug approved by the FDA in 1999 for the treatment of type II diabetes It lowers blood sugar by improving insulin resistance which as mentioned before is the hallmark of Type II diabetes It has also been noted to improve blood lipid levels Rosiglitazone works by stimulating the PPAR gamma system It is hoped that this drug can turn on the PPAR system and reverse the HIV-associated lipodystrophy syndrome
Rosiglitazone is a new drug approved by the FDA in 1999 for the treatment of type II diabetes It lowers blood sugar by improving insulin resistance which as mentioned before is the hallmark of Type II diabetes It has also been noted to improve blood lipid levels Rosiglitazone works by stimulating the PPAR gamma system It is hoped that this drug can turn on the PPAR system and reverse the HIV-associated lipodystrophy syndrome
Detailed Description:
None
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?:
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| M01RR000096 | NIH | None | httpsreporternihgovquickSearchM01RR000096 |